BioMed Nexus

FDA Sets “Trial-Free” Precedent for Ultra-Rare Disease • BioNTech Founders Pivot • Hims Lands Ozempic

Leucovorin approved using literature evidence alone as BioNTech shares drop and GLP-1 telehealth tensions ease.

Japan Approves First iPS Therapies • Xenon’s Record Epilepsy Data • FDA Eases Biosimilar Path

Azetukalner posts the strongest pivotal epilepsy efficacy ever as Vertex advances its kidney disease filing.

Servier Buys Day One for $2.5B • CBER Chief Prasad to Exit • Lonza’s $3B CDMO Pivot

MDA conference opens as MiniMed’s weak IPO and Zealand’s petrelintide data reshape the obesity race.

J&J’s 55-Day FDA Approval • CVS & Google Launch AI Health Platform • TrumpRx Stalls

Tec-Dara combo sets a new myeloma benchmark as Atavistik closes a $160M raise.

Prime Tests Two-Patient FDA Approval • Moderna’s $2.25B Patent Deal • Glenmark Flovent Win

Ultra-rare regulatory precedent meets a record LNP settlement as generics pressure hits respiratory.

Teva Lands $400M Blackstone Deal • J&J's Fifth Fast Track • UCB's $1.1B CD19 Bet

Non-dilutive capital structures dominate as TL1A race heats up.

FDA Splits Gene Therapy: uniQure Rejected, Intellia Hold Lifted

Sham-controlled Phase 3 required for AMT-130 • Roche BTK Phase 3 win • ITC probes China biotech.

Week in Review: YUVIWEL Approved | Generate's Rough Debut | 44-Day Precedent

Ascendis wins achondroplasia approval with PRV, Generate IPO falls 21%, Key March PDUFAs.

FDA's 44-Day Approval | Sarepta CEO Exits | BioMarin Pulls Roctavian

Zongertinib sets a new regulatory speed record, Generate prices $400M IPO, Gene therapy reality check.

GSK’s $950M PAH Bet: 35Pharma Deal Signals Activin Race

HS235 clinical push vs Winrevair heats up, MacroGenics lorigerlimab pause, Medtronic MiniMed IPO momentum

Novo Cuts GLP-1 Prices 50% Ahead of Federal Pricing Push

CagriSema miss reshapes obesity race • BREAKWATER doubles OS • MiniMed IPO roadshow

Gilead Pays 79% Premium for Arcellx | FDA Drafts Plausible Mechanism Pathway | Vir $1.7B Deal

CAR-T scarcity trade ignites, Ultra-rare approvals reshaped, ASCO GU positioning begins

FDA Approves Bysanti | The Single-Trial Era Begins

CStone's UK win, Compass nears NDA, Mayne's margin pivot

FDA Signals Shift to Single-Trial Standard | Insmed Guides to $1B | Madrigal Nears Blockbuster

Makary outlines single pivotal pathway | Brinsupri breakout | Eversense 365 launches with twiist

FDA Reverses Moderna RTF | J&J Onshores Cell Therapy

PDUFA set for August 5 | $1B U.S. manufacturing pivot | Merck inks Mayo AI pact.

Ocular Superiority vs. 25% Drop • Danaher Buys Masimo • Medtronic PFA Surge

Retina trial paradox • $9.9B diagnostic deal • Cardiac ablation grows 80% • J&J monthly dosing approved.

Roche Kidney Breakthrough • Sanofi's $2.4B Ocular Gamble • Medtronic Earnings

Gazyva first-ever PMN win • OCUL faces make-or-break readout today • India's $240M reshoring play.

Weekly Recap: FDA Rejects Moderna & Disc • BridgeBio Phase 3 Win • HRT Label Shift

Surrogate scrutiny intensifies • Oral achondroplasia data raises switching pressure • Lilly builds $1.5B ahead of PDUFA.

BridgeBio Phase 3 Win • FDA HRT Label Shift • Universal Flu Trial

Oral dwarfism pill outpaces prior injectable data • Hormone boxed warnings removed • Seres & Ultragenyx cut staff

Merck Keytruda Win, Madrigal $4.4B Deal, Jobs Report Surprise

First immunotherapy for platinum-resistant ovarian cancer, Viking confirms Phase 3 timeline, Healthcare adds 82k jobs.

Moderna Flu RTF • REGENXBIO CRL • FDA BHA Review

FDA cites comparator design in flu filing • Hunter syndrome application declined • CSL leadership transition

Lilly–Innovent Partnership, Takeda’s AI Strategy, J&J Recall

China-sourced drug development, AI-enabled discovery, FDA telehealth extension, and Krystal Biotech RMAT.

Priovant Phase 2 Breakthrough, REGENXBIO PDUFA Watch, Eikon IPO Down 19%

Roivant subsidiary posts rare autoimmune win, Gene therapy decision under FDA review, IPO volatility tests 2026 window

FDA “Clean Label” Enforcement Shift, TrumpRx Platform Launch

FDA grants enforcement discretion for natural colors. Plus: manufacturers join federal DTC pricing framework; Cardinal Health updates FY26 outlook.

The IPO Window Reopens: Eikon's $381M Debut | Oncology Pipeline Updates

Rare disease incentives restored, Medtronic acquires CathWorks, Eikon prices at $18.